Posizioni attive di Thomas F. Tedder
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Cellective BioTherapy, Inc.
 Cellective BioTherapy, Inc. Pharmaceuticals: MajorHealth Technology Cellective BioTherapy, Inc. engages in the research and development of novel cellular and monoclonal antibody-based platforms for treating cancers, autoimmunity, and immunodeficiency. Its proprietary pipeline and technology platform focuses on the unique aspects of B cell biology that are involved in regulating a variety of autoimmune diseases and inflammatory immune responses. The company was founded by Thomas F. Tedder in 2015 and is headquartered in Durham, NC. | Direttore/Membro del Consiglio | 01/01/2015 | - |
| Amministratore Delegato | 01/01/2015 | - | |
| Fondatore | 01/01/2015 | - |
Storia della carriera di Thomas F. Tedder
Precedenti posizioni note di Thomas F. Tedder
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Cellective Therapeutics, Inc.
 Cellective Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Cellective Therapeutics, Inc. provides biopharmaceuticals products. It develops monoclonal antibodies for the treatment of oncology and autoimmune diseases. Cellective Therapeutics products include monoclonal antibodies that target the B-cell antigens CD19, CD20 and CD22 are in preclinical stage programs. It was founded by Thomas F. Tedder and Alter E. Geller in May, 2003 and is headquartered in Durham, NC | Direttore Tecnico/Scientifico/R&S | 01/05/2003 | 14/11/2008 |
| Fondatore | 01/05/2003 | 14/11/2008 |
Statistiche
Distribuzione geografica
| Stati Uniti | 3 |
Posizioni
| Founder | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Director/Board Member | 1 |
Settori
| Health Technology | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 2 |
|---|---|
Cellective Therapeutics, Inc.
Cellective Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Cellective Therapeutics, Inc. provides biopharmaceuticals products. It develops monoclonal antibodies for the treatment of oncology and autoimmune diseases. Cellective Therapeutics products include monoclonal antibodies that target the B-cell antigens CD19, CD20 and CD22 are in preclinical stage programs. It was founded by Thomas F. Tedder and Alter E. Geller in May, 2003 and is headquartered in Durham, NC | Health Technology |
Cellective BioTherapy, Inc.
Cellective BioTherapy, Inc. Pharmaceuticals: MajorHealth Technology Cellective BioTherapy, Inc. engages in the research and development of novel cellular and monoclonal antibody-based platforms for treating cancers, autoimmunity, and immunodeficiency. Its proprietary pipeline and technology platform focuses on the unique aspects of B cell biology that are involved in regulating a variety of autoimmune diseases and inflammatory immune responses. The company was founded by Thomas F. Tedder in 2015 and is headquartered in Durham, NC. | Health Technology |
- Borsa valori
- Insiders
- Thomas F. Tedder
- Esperienza
